To then assess whether Slc25a1 is relevant to NAFLD/NASH, we performed IHC analysis of human tissue microarrays derived from the liver of patients with NASH, which showed higher expression levels relative to normal livers (Fig. 1b, top panels; quantified in Fig. 1c and Supplementary Fig. S1). This evidence concerns the gene SLC25A1 and metabolic dysfunction-associated steatotic liver disease.